Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086)

THLBB04

---

Time: 17:09
Speaker: Francois Raffi



The slides with audio are not available online


For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.